(Q46504690)

22 December 2017

title

Sildenafil citrate improves erectile function and lower urinary tract symptoms independent of baseline body mass index or LUTS severity (English)

1 reference

22 December 2017

author name string

Kevin T McVary

series ordinal

1

1 reference

22 December 2017

Richard L Siegel

series ordinal

2

1 reference

22 December 2017

Martin Carlsson

series ordinal

3

1 reference

22 December 2017

language of work or name

English

0 references

publication date

2 July 2008

1 reference

22 December 2017

published in

Urology

1 reference

22 December 2017

volume

72

1 reference

22 December 2017

issue

3

1 reference

22 December 2017

page(s)

575-579

1 reference

22 December 2017

Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.04.020

Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical "Aging Male" symptoms? Results of the "Cologne Male Survey"

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.04.020

Sexual dysfunction in the United States: prevalence and predictors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.04.020

Prevalence of erectile dysfunction and associated factors among men without concomitant diseases: a population study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.04.020

Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. European Tamsulosin Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.04.020

Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.04.020

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.04.020

Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. The Multicenter Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.04.020

Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.04.020

Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.04.020

Central obesity is an independent predictor of erectile dysfunction in older men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.04.020

Physical activity and erectile dysfunction: meta-analysis of population-based studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.04.020

Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.04.020

Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.04.020

Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.04.020

Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.04.020

Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.04.020

Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.04.020

Risk factors for lower urinary tract symptoms in elderly men. For the Prostate Study Group of the Austrian Society of Urology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.04.020

Association of risk factors and medical comorbidities with male sexual dysfunctions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.04.020

Concordance rates and modifiable risk factors for lower urinary tract symptoms in twins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.04.020

Is the metabolic syndrome an independent risk factor for erectile dysfunction?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.04.020

Prevalence of metabolic syndrome and its association with erectile dysfunction among urologic patients: metabolic backgrounds of erectile dysfunction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.04.020

Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.04.020

Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.04.020

10.1016/J.UROLOGY.2008.04.020

7 January 2021

Identifiers

DOI

1 reference

22 December 2017

1 reference

22 December 2017